Corbus Pharmaceuticals Q2 EPS exceeded expectations and analysts adjusted price targets.

Wedbush reduced its price target for Corbus Pharmaceuticals (CRBP) from $85 to $51, while Oppenheimer raised its target from $80 to $88. CRBP reported a Q2 EPS loss of $0.90, exceeding expectations of $1.19. The average target price is $65.86, with a moderate buy rating. Corbus focuses on developing cancer treatments, including CRB-701, CRB-601, and CRB-913. The company's market cap is $208.5 million, with a P/E ratio of -2.80.

September 21, 2024
3 Articles